Mizuho analyst Matthew Broome maintains Sabre (NASDAQ:SABR) with a Neutral and raises the price target from $6 to $7.
Mizuho Maintains Neutral on Sabre, Raises Price Target to $7
Mizuho analyst Matthew Broome maintains Sabre (NASDAQ:SABR) with a Neutral and raises the price target from $6 to $7.
Related Posts
Moderna Moves Forward With Second HIV Vaccine Trial
Moderna Inc (NASDAQ:MRNA) has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA…
Barclays Maintains Equal-Weight on Coinbase Global, Raises Price Target to $57
Barclays analyst Benjamin Budish maintains Coinbase Global (NASDAQ:COIN) with a Equal-Weight and raises the price target from $45 to $57.
Recap: Minerva Neurosciences Q1 Earnings
Minerva Neurosciences (NASDAQ:NERV) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:30 AM.
Here's what investors need to know about the announcement.